THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ --Amgen(NASDAQ: AMGN) today announced plans to invest an additional$300 millionin itsU.S.manufacturing network to further advanceU.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.
"Amgenhas been a leader inU.S.biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing," saidRobert A. Bradway, chairman and chief executive officer atAmgen. "By growing our operations inPuerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs."
Amgen's expansion of its biologics manufacturing facility inPuerto Ricowill strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs. Established in 1992, the company's Juncos site is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to more than 60 countries.
Amgen's latest investment builds on its broaderU.S.manufacturing expansion strategy. Over the past year, the company has announced planned investments of $650 millioninPuerto Rico, $900 millioninOhio and $600million in a science and innovation center in California. In addition,Amgenhas invested more than $1.5 billioninNorth Carolina.
"This investment confirms that the policies we have implemented are working.Puerto Ricohas more than 60 years of excellence in the biopharmaceutical sector, supported by a highly skilled workforce and world‑class infrastructure, and Amgen knows this better than anyone," said Puerto Rico Governor Jenniffer González Colón. "We will continue working to makePuerto Ricothe number one destination for advanced manufacturing inthe United States."
"Amgen's additional$300 millioncommitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here. Combined with the$650 millionpreviously announced, this represents nearly$1 billionin confidence in our workforce, our capabilities and our ability to produce life‑saving medicines," said Sebastián Negrón Reichard, Puerto Rico Secretary of theDepartment of Economic Development and Commerce. "This is the result of our commitment to building a pro‑business jurisdiction where world‑class companies likeAmgencan grow, invest and thrive."
Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017. Pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, support the company's ability to invest in domestic science and manufacturing.
About Amgen
Amgendiscovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology,Amgenreaches millions of patients with its medicines.
More than 45 years ago,Amgenhelped establish the biotechnology industry at itsU.S.headquarters inThousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today.Amgenis advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgenhas been consistently recognized for innovation and workplace culture, including honors fromFast Companyand Forbes.Amgenis one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on theNasdaq Stock Marketbased on market capitalization.